We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Delays Prasugrel Decision, Will Review Additional Data
FDA Delays Prasugrel Decision, Will Review Additional Data
June 27, 2008
The review period for Eli Lilly and Daiichi Sankyo’s antiplatelet drug prasugrel has been extended to Sept. 26 as the FDA reviews supplemental analyses that were submitted after the original NDA was filed.